Tag: Fate Therapeutics

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Fate Therapeutics

Fate Therapeutics (FATE) Downgraded to Market Perform at UBS Group

Added to Collection on: 2018-03-06 22:48:45

Tags for this article:

Money
Finance
Economy
Stock
Price?earnings ratio
UBS
Fate Therapeutics

Click the tags to see associated articles and topics

View Article Details
170636 Shares in Fate Therapeutics (FATE) Acquired by Two Sigma Investments LP

Added to Collection on: 2018-04-14 20:45:00

Tags for this article:

Price?earnings ratio
Fate Therapeutics Inc
Fate Therapeutics

Click the tags to see associated articles and topics

View Article Details
Renaissance Technologies LLC Lowers Stake in Fate Therapeutics (FATE)

Added to Collection on: 2018-05-13 20:22:30

Tags for this article:

Fate Therapeutics Inc
Fate Therapeutics

Click the tags to see associated articles and topics

View Article Details
Fate Therapeutics (NASDAQ:FATE) Receives New Coverage from Analysts at Citigroup

Added to Collection on: 2018-08-26 14:01:58

Tags for this article:

Finance
Stock market
Stock
Corporate finance
Fate Therapeutics

Click the tags to see associated articles and topics

View Article Details
Here's Why Fate Therapeutics' Data Produced a 38% Jump in the Stock Price

Added to Collection on: 2020-12-23 14:15:00

Tags for this article:

Medical specialties
Immune system
Branches of biology
Clinical medicine
Lymphocytes
Specialty drugs
Natural killer cell
T cell
Rituximab
Cancer immunotherapy
Innate lymphoid cell
Fate Therapeutics

Click the tags to see associated articles and topics

View Article Details
2 Best Biotech Stocks to Buy in January

Added to Collection on: 2021-01-28 11:37:30

Tags for this article:

BioNTech
Companies
Health sciences
Medical research
Medicine
Clinical trials
Pfizer-BioNTech COVID-19 vaccine
Pfizer
COVID-19 vaccine
Fosun Pharma
Johnson & Johnson
NASDAQ Biotechnology Index
Fate Therapeutics

Click the tags to see associated articles and topics

View Article Details
Fate Therapeutics (NASDAQ:FATE) Receives Sell (E+) Rating from Weiss Ratings

Added to Collection on: 2025-10-09 17:55:49

Tags for this article:

Alternative investment management companies
Institutional investors
Capital
Private sector
Stock market
Hedge fund
Fate Therapeutics Inc
Fate Therapeutics

Click the tags to see associated articles and topics

View Article Details
Book a Demo